Strategic US Focus Immunovia prioritizes the United States market with a clinical lab presence and a commercial footprint, presenting an opportunity to tailor sales approaches to US healthcare providers, surveillance programs, and payer ecosystems for early pancreatic cancer detection.

Early Detection Value PancreaSure targets Stage 1–2 pancreatic cancer detection, addressing high-risk populations and screening programs. This creates a compelling case for hospital systems and clinics focusing on high-risk cohorts seeking to improve mortality through earlier diagnosis.

LDT Expansion Recent launch of PancreaSure as an LDT-type test in US surveillance centers signals openness to partnership models, contract laboratories, and managed services with healthcare networks seeking accredited, flexible diagnostic solutions.

Growth Through Relocation The strategic move of U.S. operations to North Carolina’s RTP and leadership appointments indicates potential for expanded regional sales coverage, local regulatory coordination, and enhanced collaboration with nearby academic centers and payer partners.

Financial Leverage With a mid-market revenue profile and existing funding, Immunovia may be receptive to partnerships, co-development, or milestone-based commercial arrangements to accelerate adoption, clinical validation, and scale within high-value oncology surveillance programs.